Publication

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis

Arends, S., van der Veer, E., Kallenberg, C. G. M., Brouwer, E. & Spoorenberg, A., May-2012, In : CURRENT OPINION IN RHEUMATOLOGY. 24, 3, p. 290-298 9 p.

Research output: Contribution to journalReview articleAcademicpeer-review

PURPOSE OF REVIEW: Identifying the characteristics of patients with ankylosing spondylitis (AS) before start of treatment which are able to predict a beneficial response to tumor necrosis factor-alpha (TNF-α) blocking therapy is relevant, especially in view of the high costs and potential side-effects of these agents. This review provides an overview of clinical trials and observational studies investigating baseline predictors of response after 3-6 months of TNF-α blocking therapy and baseline predictors of long-term anti-TNF-α treatment continuation in AS.

RECENT FINDINGS: In multiple studies, increased acute phase reactants, higher disease activity, higher functional status, younger age, and HLA-B27 positivity were identified as independent baseline predictors of achieving clinical response to TNF-α blocking therapy. Increased acute phase reactants, presence of peripheral arthritis, and male sex were repeatedly identified as independent baseline predictors of anti-TNF-α treatment continuation.

SUMMARY: Several studies using multivariate analyses identified comparable baseline predictors of response and/or continuation of TNF-α blocking therapy. The single predictors identified have, at best, moderate capacity to predict treatment response in the individual patient. The development of a prediction model may lead to a more robust instrument to support physicians in decision making on TNF-α blocking therapy in AS in daily clinical practice.

Original languageEnglish
Pages (from-to)290-298
Number of pages9
JournalCURRENT OPINION IN RHEUMATOLOGY
Volume24
Issue number3
Publication statusPublished - May-2012

    Keywords

  • ankylosing spondylitis, biomarkers, predictors, TNF-alpha blocking therapy, treatment response, NECROSIS FACTOR TREATMENT, PLACEBO-CONTROLLED TRIAL, MAJOR CLINICAL-RESPONSE, AXIAL SPONDYLOARTHRITIS, DISEASE-ACTIVITY, DOUBLE-BLIND, 2010 UPDATE, ETANERCEPT, SAFETY, INFLIXIMAB

ID: 5536036